News | January 09, 2025
Evonik partners with South Korean ST Pharm to increase its offerings for RNA and nucleic acid delivery
Increases speed to market for drug developers working on nucleic acid therapeutics
Increases speed to market for drug developers working on nucleic acid therapeutics
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The Shasta system and Shasta Whole-Genome Amplification (WGA) Kit dramatically increase throughput for WGA by processing up to 1,500 cells per run
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
The updated COVID-19 vaccine is tailored to the KP.2 strain of the SARS-CoV-2 Omicron JN.1 lineage and is recommended for individuals 6 months of age and older
Novartis has option to acquire two future development-ready programs to augment its renal portfolio, a strategic area of focus for the company
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
CureVac receives €400 million upfront and up to an additional €1.05 billion in development, regulatory and sales milestone payments as well as tiered royalties; all previous financial considerations from the prior collaboration agreement replaced
Subscribe To Our Newsletter & Stay Updated
